Volume 6.39 | Oct 6

Hematopoiesis News 6.39 October 6, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Attacking Acute Myeloid Leukemia
Scientists demonstrated that a molecule isolated from sea sponges and later synthesized in the lab, can halt the growth of cancerous cells and could open the door to a new treatment for leukemia. [Press Release from Harvard University discussing online prepublication in Nature] Press Release | Abstract
Learn more about STEMvision automated mouse hematopoietic colony-forming unit (CFU) assay imaging and counting.
PUBLICATIONS (Ranked by impact factor of the journal)
AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow
Scientists showed that AMP-activated protein kinase (AMPK), a metabolic checkpoint kinase, confers metabolic stress resistance to leukemia-initiating cells and promotes leukemogenesis. [Cell Stem Cell]
Abstract | Graphical Abstract

Single Cell RNA-Seq Reveals Changes in Cell Cycle and Differentiation Programs upon Aging of Hematopoietic Stem Cells
Investigators used single cell RNA-seq to dissect variability in hematopoietic stem and progenitor cell populations from young and old mice from two strains. They found that cell cycle dominates the variability within each population, and that there is a lower frequency of cells in the G1 phase among old compared to young long-term hematopoietic stem cells, suggesting that they traverse through G1 faster. [Genome Res] Abstract

Epigenetic Control of Apolipoprotein E Expression Mediates Gender-Specific Hematopoietic Regulation
Scientists demonstrated that expression of a truncated DNA methyltransferase 3B isoform DNMT3B7, which has been shown to alter cellular epigenetic patterns, decreases the overall number of hematopoietic stem and progenitor cells, and markedly diminishes blood cell reconstitution within the female hormonal microenvironment. [Stem Cells] Abstract

Vascular Platform to Define Hematopoietic Stem Cell Factors and Enhance Regenerative Hematopoiesis
Investigators examined the capacity of bone marrow endothelial cells (BMECs) to support ex vivo and in vivo hematopoiesis. They demonstrated that AKT1-activated BMECs have a unique transcription factor/cytokine profile that supports functional hematopoietic stem cells in lieu of complex serum and cytokine supplementation. [Stem Cell Rep] Full Article | Graphical Abstract

The Bone Marrow Microenvironment Is Similarly Impaired in Allogeneic Hematopoietic Stem Cell Transplantation Patients with Early and Late Poor Graft Function
Investigators recently reported that bone marrow microenvironment abnormalities may occur in cases of late poor graft function (PGF). To determine whether these abnormalities occur in early PGF, they performed a nested case–control study comparing cellular elements of the bone marrow microenvironment in ten subjects with early PGF, 30 subjects with late PGF and 40 subjects without PGF. [Bone Marrow Transplant] Abstract

Kinetics of Hematopoietic Stem Cells and Supportive Activities of Stromal Cells in a Three-Dimensional Bone Marrow Culture System
The authors analyzed the kinetics of hematopoietic cells, and more than 50% of hematopoietic progenitor cells, including CFU-Mix, CFU-GM and BFU-E in three-dimensional culture were in a resting (non-S) phase. They also examined the hematopoietic supportive ability of stromal cells by measuring the expression of various mRNAs relevant to hematopoietic regulation. [Growth Factors] Abstract


Long-Term Survival Outcomes of Reduced-Intensity Allogeneic or Autologous Transplantation in Relapsed Grade 3 Follicular Lymphoma
Researchers compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning allo-HCT or first auto-HCT during 2000–2012 were included. [Bone Marrow Transplant] Abstract

A Randomized Controlled Trial of Cyclosporine and Tacrolimus with Strict Control of Blood Concentrations after Unrelated Bone Marrow Transplantation
Investigators performed a randomized controlled trial to compare cyclosporine and tacrolimus with target blood concentrations of 500 and 15 ng/ml, respectively, to prevent acute GVHD after unrelated hematopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

UM171 & UM729 - Get the Authentic Small Molecules for Ex Vivo Expansion of Human HSCs
Modeling Human Bone Marrow Failure Syndromes Using Pluripotent Stem Cells and Genome Engineering
The authors present recent progresses in disease modeling of inherited and acquired bone marrow failure syndromes using reprogramming and genome editing techniques. They also discuss the challenges and potential shortcomings of induced pluripotent stem cell based models for hematological diseases. [Mol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the Hematopoiesis research field.
The Leukemia & Lymphoma Society Commits $28.6 Million to New Cancer Research Funding
The Leukemia & Lymphoma Society announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. [Leukemia & Lymphoma Society] Press Release

Grants Support Baylor Researchers’ Work on Immunotherapy for Leukemia
Two Baylor College of Medicine researchers have received Translational Research Grants from the Leukemia and Lymphoma Society for projects that use immunotherapy approaches to treat leukemia. [Baylor College of Medicine] Press Release

Kiadis Pharma Announces Initiation of a Repeat-Dosing Phase II Clinical Trial with ATIR101™
Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, announced that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™. [Kiadis Pharma N.V.] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Global Cancer Summit
November 18-20, 2015
Bangalore, India

Visit our events page to see a complete list of events in the Hematopoiesis community.
NEW Postdoctoral Fellow – Leukemia Stem Cell Biology (Lund University)

NEW Associate Professor – Leukemia Research (University of Heidelberg)

NEW Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Postdoctoral Positions – Cancer and Developmental Biology (North Carolina Central University)

Assistant Professor – Stem Cell Biology (University of South Carolina)

Postdoctoral Position – Hematology and Immunology (University of Liege)

Director of Research – Oncology and Hematology (CancerCare Manitoba)

Postdoctoral Fellow – HMGA Chromatin Remodeling Proteins in Cancer and Stem Cell Biology (Johns Hopkins University School of Medicine)

Regulatory Coordinator – Leukemia (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us